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Abstract Adrenoleukodystrophy (ALD) is an X-linked dis-
order affecting primarily the white matter of the central
nervous system occasionally accompanied by adrenal insuffi-
ciency. Despite the discovery of the causative gene, ABCD1,
no clear genotype–phenotype correlations have been estab-
lished. Association studies based on single nucleotide poly-
morphisms (SNPs) identified by comprehensive resequencing
of genes related to ABCD1 may reveal genes modifying ALD
phenotypes. We analyzed 40 Japanese patients with ALD.
ABCD1 and ABCD2 were analyzed using a newly developed
microarray-based resequencing system. ABCD3 and ABCD4
were analyzed by direct nucleotide sequence analysis.
Replication studies were conducted on an independent
French ALD cohort with extreme phenotypes. All the
mutations of ABCD1 were identified, and there was no
correlation between the genotypes and phenotypes of ALD.
SNPs identified by the comprehensive resequencing of
ABCD2, ABCD3,a n dABCD4 were used for association
studies. There were no significant associations between these
SNPs and ALD phenotypes, except for the five SNPs of
ABCD4, which are in complete disequilibrium in the
Japanese population. These five SNPs were significantly less
frequently represented in patients with adrenomyeloneurop-
athy (AMN) than in controls in the Japanese population (p=
0.0468), whereas there were no significant differences in
patients with childhood cerebral ALD (CCALD). The
replication study employing these five SNPs on an indepen-
dent French ALD cohort, however, showed no significant
associations with CCALD or pure AMN. This study showed
that ABCD2, ABCD3,a n dABCD4 are less likely the disease-
modifying genes, necessitating further studies to identify
genes modifying ALD phenotypes.
Keywords Adrenoleukodystrophy.ABCD1.ABCD2.
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Introduction
Adrenoleukodystrophy (ALD) is a demyelinating disease
caused by mutations of ABCD1 [1]. This disease affects
primarily the white matter of the central nervous system
occasionally accompanied by adrenal insufficiency [2–4].
Diagnosis of ALD is usually made by the increased contents
of very long chain saturated fatty acids (VLCFAs; >C22:0)
in plasma as well as by mutational analysis of ABCD1 [5–7].
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DOI 10.1007/s10048-010-0253-6Since 15% of obligate female carriers have normal VLCFA
levels [7], mutational analysis is essential for the diagnosis of
the carriers. Since the first report of allogenic HSCT for
childhood ALD, there has been an increasing number of
reports showing efficacies of HSCT for the childhood
cerebral form of ALD, if HSCT is performed at early stages
of the disease [8–10]. Thus, availability of rapid molecular
diagnosis for patients with ALD and carriers is mandatory in
the clinical practice for ALD.
ALD is characterized by a broad spectrum of clinical
presentations including childhood cerebral form, adreno-
myeloneuropathy (AMN), AMN complicated by cerebral
demyelination, adulthood cerebral form, and Addison
disease. From clinical experience, patients with different
clinical phenotypes can be observed even in a single
pedigree. In support of this, no clear genotype–phenotype
correlations have been observed [11–16], raising the
possibility that other genetic or environmental factors are
involved in the pleiomorphic clinical presentations of ALD.
ABCD1 gene encodes a half-ATP-binding cassette (ABC)
transporter, adrenoleukodystrophy protein (ALDP), which is
localized to the peroxisomal membrane. ABCD2, ABCD3,a n d
ABCD4 genes are the closest homologues of the ABCD1 gene
[17, 18]. It has been shown that the majority of mouse liver
ALDP and the 70-kDa peroxisomal membrane protein
(PMP70) that is encoded by ABCD3 are homomeric proteins
[19]. Furthermore, it has been shown that ALDP can form
homodimers or a heterodimer with the adrenoleukodystrophy-
related protein (ALDR) that is encoded by ABCD2 or the
PMP70 that is encoded by ABCD3 [16, 20–22], raising the
possibility that these ABCD1-related genes function as
disease-modifying genes for ALD.
To provide a rapid mutational analysis for ALD, we
developed a microarray-based high-throughput resequenc-
ing system of ABCD1 (TKYPD01) [23]. Furthermore, to
explore the possibility that these ABCD1-related genes
function as disease-modifying genes, we established a
comprehensive resequencing system for ABCD1-related
genes, ABCD2, ABCD3, and ABCD4. On the basis of the
comprehensive resequencing of ABCD1, ABCD2, ABCD3,
and ABCD4 genes, we identified 11 novel single nucleotide
polymorphism (SNPs). Using these novel SNPs as well as
previously described SNPs of these genes, we conducted
detailed association studies of these SNPs with the clinical
phenotypes of ALD.
Materials and methods
Participants
Forty Japanese ALD patients, consisting of 14 patients with
childhood cerebral ALD (CCALD), 8 patients with adult-
hood cerebral ALD (AdultCer), 2 patients with AMN with
later development of cerebral ALD (AMN-Cer), 13 patients
with AMN, 1 asymptomatic patient, and 2 patients with
unknown form, were enrolled in this study. Among the
patients, mutations were previously identified in 16 ALD
patients by direct nucleotide sequence analysis, while no
mutational analyses were conducted for 24 patients.
For replication studies of the results of association studies
on Japanese ALD patients showing potential associations of
SNPs in ABCD1-related genes with ALD phenotypes, an
independent French ALD cohort with well-defined extreme
phenotypes consisting of 118 patients with CCALD and 71
patients with pure AMN (AMN with age >45 years as well
as with normal brain magnetic resonance imaging) was
studied. In addition, 51 ALD patients with AMN-Cer were
also analyzed in the French ALD cohort.
Procedures
Primers specific for ABCD1, ABCD2, ABCD3, and ABCD4
were designed using BLAST search and Smith–Waterman
method to avoid amplification of the related homologous
genes (Fig. 1; ESM Tables 1, 2, 3, and 4). In particular,
since there were many segments homologous to exons 8, 9,
and 10 of ABCD1, a specific primer pair was designed
(Fig. 1). Fifty nanograms of genomic DNAwere subjected to
polymerase chain reaction (PCR) amplification in a total
volume of 50 μL. The PCR conditions were as follows: 94°C
for 1 min, followed by five cycles consisting of 94°C for
30 s, 62°C for 30 s, and 68°C for 2 min; five cycles
consisting of 94°C for 30 s, 60°C for 30 s, and 68°C for
2 min; and 25 cycles consisting of 94°C for 30 s, 58°C for
30 s, and 68°C for 2 min, followed by a final extension at
68°C for 7 min, using the LA Taq with GC Buffer PCR
system (Takara Bio, Otsu, Shiga, Japan).
Resequencing DNA microarrays were used in the analyses
of the sequences of ABCD1 (TKYPD01) and ABCD2
(TKYAD01). TKYPD01 and TKYAD01 were designed
using the platform of GeneChip CustomSeqTM Resequenc-
ing Microarray (Affymetrix, Santa Clara, CA, USA). Since
there are substantial homologies between ABCD1 and
ABCD2, these genes were placed in independent microarrays
(TKYPD01 and TKYAD01). Each PCR product of ABCD1
and ABCD2 was quantified using PicoGreen (Molecular
Probes, Eugene, OR, USA) and equimolarly pooled. Pooled
PCR products of ABCD1 and ABCD2 were fragmented
using DNAse I, labeled with biotin, hybridized to DNA
microarrays, and subjected to scan and analyses of nucleo-
tide sequences of ABCD1 (TKYPD01) and ABCD2
(TKYAD01) according to the manufacturer's instructions
(Affymetrix, Santa Clara, CA, USA). The base calls that
were undetermined using the GDAS analysis software
(Affymetrix, Santa Clara, CA, USA) were further analyzed
42 Neurogenetics (2011) 12:41–50by manual inspection. Identified mutations and SNPs were
confirmed by the direct nucleotide sequence analysis of the
PCR products. All the PCR products of ABCD3 and ABCD4
were analyzed by the direct nucleotide sequence analysis.
Identified SNPs of ABCD2, ABCD3,a n dABCD4 were
examined as to whether they were novel SNPs or known
SNPs using the J SNP (http://snp.ims.u-tokyo.ac.jp/index_ja.
html) and DB SNP (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=Snp&cmd=Limits).
Statistical analyses
We compared the allele frequencies of detected SNPs
between the subgroups of ALD or between the individual
subgroup and the controls by Fisher's exact test using the
JMP 7 software (SAS Institute, Cary, NC, USA). Deviation
of the SNP genotypes from the Hardy–Weinberg equilibri-
um was evaluated using the PEDSTATS program [24].
Linkage disequilibria among the neighboring SNPs were
evaluated using Haploview version 4.1 [25].
Results
Resequencing DNA microarray-based mutational analysis
of ABCD1 gene in Japanese ALD patients
All the mutations of ABCD1 were clearly identified using
the resequencing DNA microarray system including 26
missense, 2 nonsense, and 12 insertion/deletion mutations
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Fig. 2 Scan data of the
resequencing DNA microarray
and sequence data of the direct
nucleotide sequence analysis
(upper panel: patient, lower
panel: control). Each column
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row shows a base call DNA in
the scan data of the resequenc-
ing DNA microarray. Here, a
mutation (G277R) was detected,
and the signal intensities around
the mutation were reduced
because of the mismatch of the
mutation site. The sequence data
of the direct nucleotide sequence
analysis confirmed the scan data
of the resequencing
DNA microarray
ABCD1 regions with homologies to pseudogenes
5’ 3’ 5 3
E 12 3 4 5 6 7 8 9 1 0 Exon 12 3 4 5 6 7 8 9 1 0
1F 1R 2F 2R 3F 4R 5F 5R 6F 7R 8F 10R
Primer pairs Primer pairs
Forward primer for exons 8 10: Designed to allow specific Forward primer for exons 8-10: Designed to allow specific
amplification of ABCD1 amplification of ABCD1
CCT GGGGCTGCCA T AAACCGCAGGGA T GGA TTGT CT C ABCD1
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2p11
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CCT GGGGCTGCCA T AAACCGCAGGGGT GGA T CA T CT C
10p11
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Fig. 1 Primer design for
ABCD1. All the exons of
ABCD1 were amplified using
six primer pairs. There were
pseudogenes at 2p11, 10p11,
16p11, and 22q11, which were
similar in sequence to exons
7–10 of ABCD1 gene (92–96%).
The forward primer for exons
8–10 was designed to avoid
amplification of the related
homologous genes. We could
design a specific reverse
primer for exons 8–10
Neurogenetics (2011) 12:41–50 43of ABCD1 (Figs. 2 and 3; Tables 1 and 2). Mutations of
ABCD1 gene were widely scattered in the entire region of
ABCD1 gene (Fig. 3; Tables 1 and 2). All types of ABCD1
mutation were distributed among all the phenotypes of
ALD (Fig. 3; Tables 1 and 2). Among the 40 mutations, 11
mutations were novel (Tables 1 and 2). Among the deletion/
frameshift mutations that are expected to result in complete
loss of ALDP functions, the mutations were distributed
among all the phenotypes of ALD (Tables 1 and 2),
supporting the previous observations of no genotype–
phenotype correlations.
Identification of SNPs of ABCD2, ABCD3, and ABCD4
genes by comprehensive resequencing
Comprehensive resequencing of ABCD2, ABCD3,a n d
ABCD4 genes of the 40 Japanese patients with ALD
revealed two novel SNPs, nine SNPs (six known and three
novel SNPs), and 13 SNPs (seven known and six novel
SNPs), respectively (Fig. 4; Tables 3, 4, 5, and 6; ESM
Table 5). Hardy–Weinberg equilibrium was fulfilled for
each SNP. The five known SNPs (rs17782508, rs2301345,
rs4148077, rs4148078, and rs3742801) were in complete
Table 1 Identified ABCD1 mutations: mutations of ABCD1 that result in devastating effects (frame shifts or nonsense mutations) on
adrenoleukodystrophy protein (ALDP)
Patient number Phenotype Mutation of ABCD1 Effect of mutation of ABCD1
1 CCALD 488C>AT Frameshift at P34
2 CCALD 2171G>A W595X
3 CCALD 5′UTR-Ex2 1.4-kb deletion
a Disruption of gene structure
4 AdultCer Del. 986C
a Frameshift at D200
5 AdultCer Del. 1801–1802AG
a Frameshift at Q472
6 AMN-Cer Del. 2251 GGTG ins. TGTTCT
a Frameshift at R622
7 AMN Ins. 1237T
a Frameshift at Y281
8 AMN Del. 1801–1802AG
a Frameshift at Q472
9 AMN 2171G>A W595X
10 AMN Del. 2251 GGTG ins. TGTTCT
a Frameshift at R622
11 Unknown Del. 1541C
a Frameshift at F385
12 Unknown Ex8-10 0.3-kb deletion
a Disruption of gene structure
Amino acid residue numbers in ALDP are based on Mosser et al. [1]. The domains and motifs in the ALDP are based on Mosser et al. [1]
CCALD childhood cerebral ALD, AdultCer adult with cerebral ALD, AMN-Cer AMN with cerebral ALD, AMN adrenomyeloneuropathy, TM
transmembrane domain, Loop 1 loop 1 motif, EAA-like EAA-like protein motif, Walker AWalker A motif, Cons nucleotide binding fold conserved
sequence, Walker B Walker B motif
aNovel mutation
ABCD1
TM3 TM5
Wl k A C sequence TM1 TM2 TM4 EAA-like TM6 Walker A Walker B C sequence
5’ 3’
del. Ex8-10
Exon1 Exon2 Exon3 Exon5 Exon6 Exon7 Exon8 Exon9 Exon10
fs at F385
Clinical phenotypes of ALD
asymptomatic or unknown: Black   
Fig. 3 Identified mutations of
ABCD1. Mutations of ABCD1
gene were widely scattered in
the entire region of ABCD1
gene. All types of ABCD1
mutations were distributed
among all the phenotypes of
adrenoleukodystrophy. TM
transmembrane domain, EAA-
like EAA-like protein motif,
Walker A Walker A motif, C
sequence nucleotide binding
fold conserved sequence, Walker
B Walker B motif, fs frameshift
44 Neurogenetics (2011) 12:41–50linkage disequilibrium in the Japanese patients with ALD
as well as in the controls, as determined using Haploview
version 4.1 (Fig. 4).
Association studies of SNPs of ABCD2, ABCD3,
and ABCD4 with the clinical phenotypes of ALD
Using the 11 novel SNPs and 13 previously described SNPs
in ABCD2, ABCD3, and ABCD4, we conducted association
studies of these SNPs with the clinical phenotypes of ALD
(Tables 5 and 6).
For ABCD2, we analyzed two novel SNPs (novel SNP1
and novel SNP2). There were no significant differences in
the allele frequencies between patients with cerebral form
and those with AMN, or between the patients with individual
phenotypes of ALD and the controls. For ABCD3,w e
analyzed three novel SNPs (novel SNP3, novel SNP4, and
novel SNP5) and six previously described SNPs (rs4148058,
rs2147794, rs16946, rs681187, rs662813, and rs337592).
However, we did not also detect any significant associations.
For ABCD4, we analyzed six novel SNPs (novel SNP6,
novel SNP7, novel SNP8, novel SNP9, novel SNP10, and
novel SNP11) and seven previously described SNPs
(rs17782508, rs17182959, rs17158118, rs2301345,
rs4148077, rs4148078, and rs3742801). Interestingly, the
five previously described SNPs (rs17782508, rs2301345,
rs4148077, rs4148078, and rs3742801) that are in complete
linkage disequilibrium were significantly less frequently
represented in the patients with Japanese AMN than in the
controls in the Japanese population (p=0.0468), whereas
Table 2 Identified ABCD1 mutations: mutations of ABCD1 that result in amino acid substitutions or in-frame deletions
Patient number Phenotype Mutation of ABCD1 Effect of mutation of ABCD1 Position of mutation
13 CCALD 709C>T S108L Loop1
14 CCALD 709C>T S108L Loop1
15 CCALD 829A>G N148S TM2
16 CCALD 1026A>G N214D TM3
17 CCALD 1182G>A G266R Between TM4 and EAA-like
18 CCALD 1324T>C
a L313P Between EAA-like and TM5
19 CCALD 1938C>T R518W Walker A
20 CCALD 1939G>A R518Q Walker A
21 CCALD 2017A>G Q544R Between Walker A and Cons
22 CCALD 2017A>G Q544R Between Walker A and Cons
23 CCALD 2065C>T P560L Between Walker A and Cons
24 CCALD 2065C>T P560L Between Walker A and Cons
25 CCALD Del. 2145–2156 Del. HILQ587-590 Between Walker A and Cons
26 AdultCer Del. 1257–1259 Del.E291 EAA-like
27 AdultCer 2005T>C F540S Between Walker A and Cons
28 AdultCer 2358C>T R660W C-terminal to Walker B
29 AdultCer 2385C>A H667N C-terminal to Walker B
30 AMN-Cer 1146A>C T254P TM4
31 AMN 636C>T P84S TM1
32 AMN 709C>T S108L Loop1
33 AMN 1182G>A G266R Between TM4 and EAA-like
34 AMN 1197G>A E271K Between TM4 and EAA-like
35 AMN 1215G>A
a G277R Between TM4 and EAA-like
36 AMN 1255C>G S290W EAA-like
37 AMN 1581C>T R401W Between TM6 and Walker A
38 AMN 2233C>A A616D Cons
39 AMN 2385C>A H667N C-terminal to Walker B
40 Asymptomatic 2211G>A E609K Cons
Amino acid residue numbers in ALDP are based on Mosser et al. [1]. The domains and motifs in the ALDP are based on Mosser et al. [1]
CCALD childhood cerebral ALD, AdultCer adult with cerebral ALD, AMN-Cer AMN with cerebral ALD, AMN adrenomyeloneuropathy, TM
transmembrane domain, Loop 1 loop 1 motif, EAA-like EAA-like protein motif, Walker AWalker A motif, Cons nucleotide binding fold conserved
sequence, Walker B Walker B motif
aNovel mutation
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Fig. 4 Identified single nucleotide polymorphisms (SNPs) of ABCD2,
ABCD3, and ABCD4 (upper panel). Comprehensive resequencing of
ABCD2, ABCD3,a n dABCD4 genes of the 40 patients with
adrenoleukodystrophy (ALD) revealed two novel SNPs, nine SNPs
(six known and three novel SNPs), and 13 SNPs (seven known and
six novel SNPs), respectively. Red characters indicate the novel
SNPs, blue characters indicate the SNPs identified in the coding
region, and black characters indicate the SNPs identified in the
noncoding region. Linkage disequilibrium (LD) map of SNPs of
ABCD4 in Japanese patients with ALD and the controls using the
Haploview version 4.1 (lower panel) .T h ef i v ek n o w nS N P s
(rs17782508, rs2301345, rs4148077, rs4148078, and rs3742801) were
in complete disequilibrium in Japanese patients with ALD and the
controls (LOD=43.97, r
2=1.0, D′=1.0). Novel SNP7 and the five
known SNPs (rs17782508, rs2301345, rs4148077, rs4148078, and
rs3742801) were not in strong disequilibrium in Japanese patients
with ALD and the controls (LOD=1.15, r
2=0.037, D′=0.706),
although novel SNP7 and the five known SNPs (rs17782508,
rs2301345, rs4148077, rs4148078, and rs3742801) were strong
disequilibrium only in Japanese patients with ALD (LOD=2.02, r
2=
0.221, D′=1.0). The number in the box indicates the data of D′. The
color of the box is determined from the LOD score and D′. The block
was determined using a confidence interval algorithm [33]
Table 3 Summary of identified single nucleotide polymorphism (SNPs) of ABCD2, ABCD3, and ABCD4 in 40 adrenoleukodystrophy patients:
novel SNPs
Gene Name Fragment Position (UCSC hg18) Base call Category Amino acid change
ABCD2 Novel SNP1 Exon1 38299954 A/T 5′ untranslated region
Novel SNP2 Exon1 38299659 G/C Coding nonsynonymous A9G
ABCD3 Novel SNP3 Exon4 94706096 A/G Coding nonsynonymous M94V
Novel SNP4 Exon14 94727816 T/G Intron
Novel SNP5
a Exon15 94728352 G/C Intron
ABCD4 Novel SNP6 5′UTR 73840784 T/C Upstream at the transcription start site
Novel SNP7 5′UTR 73839945 T/C Upstream at the transcription start site
Novel SNP8 5′UTR 73839604 G/A Upstream at the transcription start site
Novel SNP9
b Exon12 73826720 A/G Intron
Novel SNP10 Exon18 73823320 A/G Intron
Novel SNP11
a Exon18 73823116 T/C Intron
A total of 24 SNPs of ABCD2, ABCD3, and ABCD4 were identified in 40 ALD patients. Among them, 11 SNPs (45.8%) were novel SNPs. The
positions of these novel SNPs were based on the UCSC genome browser hg18
aThese SNPs were identified only in the cerebral form (childhood cerebral ALD and adult with cerebral ALD)
bThese SNPs were identified only in the AMN form
46 Neurogenetics (2011) 12:41–50there were no significant differences in the Japanese
patients with the cerebral form compared with the controls
(Tables 5 and 6).
Given the significant association of the five SNPs
(rs17782508, rs2301345, rs4148077, rs4148078, and
rs3742801) with the phenotypes of AMN, we then
conducted a replication study on an independent French
ALD cohort with extreme phenotypes (117 CCALD cases
and 71 pure AMN cases). However, we did not find any
significant association of these five SNPs with AMN or
CCALD. Interestingly, the combination of two intronic
SNPs (A (rs17182959) and G (rs7158118)) was signifi-
cantly more frequently represented in the 51 patients with
AMN-Cer than in those with CCALD in the French ALD
cohort (p=0.0049). The combination of these two intronic
SNPs (A (rs17182959) and G (rs7158118)), however, was
not present in any of the Japanese patients with ALD,
although one combination of two intronic SNPs (A
(rs17182959) and G (rs7158118)) was present in the
Japanese controls (Tables 5 and 6 ; ESM Table 5).
Discussion
Our microarray-based high-throughput mutational analysis
system was accurate to detect all the mutations, which were
confirmed by direct nucleotide sequence analysis. This
system should be highly useful for the mutational analysis
of ABCD1 for the diagnosis of patients with ALD, and the
diagnosis of the carriers with ALD.
Gene Fragment SNP ID Category Amino acid change
ABCD3 Exon1 rs4148058 5′ untranslated region
Exon2 rs2147794 Intron
Exon3 rs16946 Coding synonymous
Exon7 rs681187 Intron
Exon23 rs662813 3′ untranslated region
Exon23 rs337592 3′ untranslated region
ABCD4 5′UTR rs17782508
a Upstream at the transcription start site
Intron1 rs17182959 Intron
Intron1 rs17158118 Intron
Exon3 rs2301345
a Coding synonymous L62L
Exon9 rs4148077
a Coding nonsynonymous A304T
Exon10 rs4148078
a Coding synonymous L320L
Exon11 rs3742801
a Coding nonsynonymous E368K
Table 4 Summary of identified
single nucleotide polymorphism
(SNPs) of ABCD2, ABCD3, and
ABCD4 in 40 adrenoleukodys-
trophy patients: known SNPs
A total of 24 SNPs of ABCD2,
ABCD3, and ABCD4 were
identified in 40 ALD patients.
Among them, 11 SNPs (45.8%)
were novel SNPs. The positions
of these novel SNPs were based
on the UCSC genome
browser hg18
aThese SNPs were in complete
disequilibrium in the
Japanese population
Table 5 Association studies of detected single nucleotide polymorphism (SNPs) with the clinical phenotypes of Japanese adrenoleukodystrophy
patients: novel SNPs
Gene SNP name Allele frequency (number) p value
a
Cerebral form
(a total of 44
chromosomes)
AMN (a total of 26
chromosomes)
Control (number of
detected SNPs/total
number)
Cerebral
form vs AMN
Cerebral
form vs control
AMN vs
control
ABCD2 Novel SNP1 3 0 5/164 0.2894 0.3700 1.0000
Novel SNP2 1 0 3/164 1.0000 1.0000 1.0000
ABCD3 Novel SNP3 1 0 0/164 1.0000 0.2115 1.0000
Novel SNP4 0 0 3/134 1.0000 1.0000 1.0000
Novel SNP5 1 0 0/160 1.0000 0.2157 1.0000
ABCD4 Novel SNP6 17 9 67/164 0.8019 0.8635 0.6680
Novel SNP7 2 1 2/164 1.0000 0.1974 0.3585
Novel SNP8 1 0 5/164 1.0000 1.0000 1.0000
Novel SNP9 0 1 0/164 0.3714 1.0000 0.1368
Novel SNP10 4 5 14/160 0.2766 1.0000 1.0000
Novel SNP11 1 0 5/160 1.0000 1.0000 1.0000
aResults of two-sided Fisher's exact test
Neurogenetics (2011) 12:41–50 47Although reverse transcription (RT)-PCR has been pref-
erentially used for the analysis of ABCD1 gene [11, 12, 26]
to overcome the difficulty of specifically amplifying the
ABCD1 gene owing to the existence of the related highly
homologous genes [13, 27], primers allowing the specific
amplification of ABCD1 enable the PCR analysis of genomic
DNA, which is much easier than RT-PCR analysis. Similar
approaches have also been used for SSCP-based [13, 28]a n d
DNA-based diagnostic testing methods [29].
In the Japanese ALD patients, mutations of ABCD1 gene
were widely scattered in the entire region of ABCD1 gene.
All types of ABCD1 mutation were distributed among all
the phenotypes of ALD, including childhood cerebral form,
AMN, and adulthood cerebral form, suggesting that there is
no association of a particular phenotype of ALD with
individual mutations as previously observed in other ALD
populations [1, 11–13, 15]( http://www.x-ald.nl/). Even
among the frameshift mutations that are clearly expected
to cause a complete loss of ALDP functions, such ABCD1
mutations were distributed among all the phenotypes of
ALD.
On the basis of the comprehensive resequencing of
ABCD2, ABCD3, and ABCD4 genes, we searched for SNPs
of these related genes to explore the possibility of these
genes as candidate disease-modifying genes for ALD,
although it was shown that ALD phenotypes are indepen-
dent of ABCD2 genotype in two independent association
studies of ABCD2 polymorphisms and ALD phenotypes
[30]. Although our study did not reveal SNPs significantly
associated with the clinical phenotypes irrespective of the
ethnic background, the SNPs in ABCD4 with suggestive
association in the Japanese patients (rs17782508, rs2301345,
rs4148077, rs4148078, and rs3742801) and French patients
(rs17182959 and rs7158118) may still deserve further
investigation including association studies on other indepen-
dent cohorts and studies on the biological effects related to
these SNPs. Among the SNPs with suggestive association in
the Japanese patients (rs17782508, rs2301345, rs4148077,
rs4148078, and rs3742801), rs4148077 (A304T) substitutes
a hydrophilic amino acid for a hydrophobic amino acid, and
rs3742801 (E368K) substitutes a basic amino acid for an
acidic amino acid. It would be interesting to investigate if
these amino acid substitutions may have relevance to the
function of ABCD4.
In this study, we identified as many as 11 novel SNPs in
ABCD2, ABCD3, and ABCD4 genes in addition to the 13
previously described SNPs. These findings indicate that
there are still numerous novel SNPs with the number
comparable to that of previously described SNPs; further-
more, this study places great emphasis on the role of
comprehensive resequencing in the discovery of novel
SNPs in relevant genes. The novel SNPs as well as
previously described ones in ABCD2, ABCD3, and ABCD4
genes should be useful for further association studies on
ALD and other peroxisome diseases and on the biological
implications associated with these SNPs.
Table 6 Association studies of detected single nucleotide polymorphism (SNPs) with the clinical phenotypes of Japanese adrenoleukodystrophy
patients: known SNPs
Gene SNP ID Allele frequency (number) p value
b
Cerebral form (a total
of 44 chromosomes)
AMN (a total of
26 chromosomes)
Control (number of
detected SNPs/total
number)
Cerebral
form vs AMN
Cerebral
form vs control
AMN vs
control
ABCD3 Rs4148058 11 5 22/164 0.7697 0.1010 0.3820
Rs2147794 6 2 34/152 0.7009 0.2880 0.0740
Rs16946 6 3 35/164 1.0000 0.2933 0.3019
Rs681187 17 9 75/158 1.0000 0.3109 0.2890
Rs662813 18 10 42/152 1.0000 0.0984 0.1435
Rs337592 2 4 19/152 0.1855 0.1714 0.7512
ABCD4 Rs17782508
a 9 2 42/164 0.1921 0.5575 0.0468
Rs17182959 10 7 40/128 0.5599 0.3386 0.8163
Rs17158118 10 7 33/162 0.5599 0.8344 0.4454
Rs2301345
a 9 2 42/164 0.1921 0.5575 0.0468
Rs4148077
a 9 2 42/164 0.1921 0.5575 0.0468
Rs4148078
a 9 2 42/164 0.1921 0.5575 0.0468
Rs3742801
a 9 2 42/164 0.1921 0.5575 0.0468
aFive SNPs (rs17782508, rs2301345, rs4148077, rs4848078, and rs3742801) were in complete disequilibrium in the Japanese population
bResults of two-sided Fisher's exact test
48 Neurogenetics (2011) 12:41–50The diverse phenotypic variations of ALD still remain
enigmatic. Recent studies suggest the role of perosixomes
of oligodendrocytes in axonal loss and neuroinflammation
[31] and microglial apoptosis as an early pathogenic change
in CCALD [32]. With the advancement in our understand-
ing of the pathophysiology of ALD, we hope that we can
further probe into the disease-modifying factors on the
basis of the molecular pathogenesis of ALD. Genome-wide
association studies may well serve as an alternative
approach for the identification of disease-modifying genetic
factors.
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